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The effect of oleic acid on losartan transdermal permeation has been observed to explore its 
ability as chemical enhancer.  Potassium losartan solutions in citric buffer pH 5.0 were made 
in two levels of concentration i.e. 2 mg/mL and 10 mg/mL using propylene glycol 15% as 
solubilizing agent. Losartan transport from such solutions with and without oleic acid one hour 
pretreatment were tested using male Wistar rat skin as a membrane for 30 hours in vertical 
diffusion sel.  The transport profiles were analyzed based on the lag time diffusion method.  It 
is showed that oleic acid pretreatment did not effect on losartan permeation rate and efficiency 
of 2 mg/mL potassium losartan concentration. However, such pretreatment enhanced losartan 
permeation rate and efficiency 21 and 23-fold higher respectively for 10 mg/mL the potassium 
losartan concentration.  It is predicted that losartan minimum effective plasma concentration 
can be achieved in transdermal administration through this transport improvement in normal 
application area. 
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INTRODUCTION
Losartan(1-((2’-(2H-tetrazol-5-il)bifenil-4-il)metil)-
2-butil-4-kloro-1H-imidazol-5-il)methanol) is the first 
Angiotensin II Receptor Antagonist available in the 
market (Ripley and Hirsch 2010).  The administration 
of losartan in diabetic-hypertension complication shows 
a significant advantages (Murthy, Kommineni, and 
Mayuren, 2013; Pan et al., 2015).   Moreover, losartan 
also has an ability to protect the liver against ischemia 
(Koh, Yoon, and Lee, 2013). 
This compound has low oral bioavailability (0.33) 
(Ripley and Hirsch 2010) due to the intensive first pass 
effect by CYP2C9 and CYP3A4 (Dina and Jafari, 2000) 
and  active efflux transporter activity (Soldner et al., 
2000). Transdermal delivery can be used to solve oral 
bioavailability problem (Tanner and Marks, 2008). 
Unfortunately, only few drugs can permeate through the 
skin due to the high resistance of stratum corneum.  The 
epidermis, especially the outermost layer, the stratum 
corneum, consists of the nearly solid dead cell which is 
very difficult to be penetrated.  The intercellular region of 
such dead cell comprises of lipid in lamellar organization 
(Bouwstra, Gooris, and Ponec, 2008).  Such situation is 
an ideal barrier for many substances to be delivered via 
transdermal (Haftek, 2014).  However, application of 
chemical enhancer can be developed to solve the barrier 
properties of skin (Paudel et al., 2010).
Vashisth and coworkers reported the potential chemical 
enhancer for transdermal delivery of losartan, such as tea 
tree oil, cumin oil, rose oil, and Aloe vera oil (Vashisth 
et al., 2014).  Capsaicin also can be used as enhancer of 
losartan from transdermal patch dosage form (Petkar and 
Kuchekar, 2007).  The usage of proniosome carrier for 
losartan transdermal delivery also enhances the rate of 
losartan permeation across the skin (Thakur et al., 2009). 
Oleic acid is an enhancer which is frequently used.  It has 
been proved that oleic acid can enhance skin permeation 
of many compounds i.e. piroxicam (Park et al., 2005), 
fisostigmin (Meshulam et al., 1993), and retinoid 
(Moghimi, Noorani, and Zarghi, 2010), both in in vitro as 
well as in vivo observation.  Such enhancement activity 
is mediated by combination of two mechanisms: lipid 
fluidization and lipid phase separation. The intercalation 
of cis-structure oleic acid into lipid lamellar of stratum 
corneum induces the lipid disordering resulting the 
fluidity enhancement similar to the effect of temperature 
increasing.  Additionally, oleic acid application can 
extract the lipid stratum corneum and decrease the 
membrane thickness (Naik, Pechtold, and Potts, 1995).
 
In the development of transdermal drug delivery, in 
vitro evaluation should be followed by an in vivo 
experiment to evaluate the efficiency of such delivery 
system.  Prediction of in vivo results is required as an 
effort to select a system in the case of many formulation 
showing distinctive advantages regarding in vitro data of 
steady state flux and lag time diffusion. Some research 
conducted the prediction of in vivo data based on in 
vitro observation using exclusive software. Nakamura 
and coworkers for instance, succeeded to predict the 
tulobuterol pharmacokinetics profile from transdermal 
delivery based on in vitro observation using SKIN CAD 
software (Nakamura, Mori, and Tojo, 2012).  
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This research was aimed to enhance losartan in vitro skin 
permeation using oleic acid pretreatment, and use such 
data, in particular the most frequent parameters calculated 
in in vitro transdermal experiment, i.e. steady state flux 
and lag time diffusion to predict the pharmacokinetics 
profile.  The prediction was constructed uncomplicatedly 
using equation derived from intra venous infusion 




In vitro observation was conducted using vertical type 
diffusion cell (Figure 1) produced by Material Process 
Laboratory, Department of Engineering Physics, The 
Bandung Institute of Technology, with fresh male Wistar 
rat skin as membrane.  The rats were purchased from 
Animal Handling Laboratory, Faculty of Pharmacy, 
Gadjah Mada University, Yogyakarta. By controlling 
the rat age (2 months) and weight (about 200 g), 
it was assumed that all membranes have the same 
thickness. Potassium losartan as active compound was 
purchased from PT Kalbe Farma Jakarta. Oleic acid as 
chemical enhancer (E Merk) was purchased from Asia 
Lab Yogyakarta.  Losartan concentration in receptor 
compartment (calculated as potassium losartan) was 
measured according previous research (Binarjo and 
Nugroho, 2013). Briefly, HPLC (Shimadzu) controlled 
using LC Solution software (Shimadzu) was equipped 
with C-18 (Lichrospher RP 18 250-4 (5 µm)) as stationary 
phase and UV detector set up at 223 nm.  Acetonitrile-
acetic buffer pH 4 in a volume ratio of 3:2 was used as 
mobile phase in an isocratic rate of 0.75 mL/minute.
The medium used for preparing drug formulation 
was 0.05 M citric buffer pH 5.0 (contain citric acid 
0.37 g/L, sodium citric 0.96 g/L, sodium chloride 4 
g/L; and mannitol 2 g/L). Propylene glycol was used 
as solubilizing agent in a concentration of 15%.  As 
acceptor medium, 0.15 M phosphate buffer saline (PBS) 
pH 7.4 (contains NaCl 8 g/l, Na2HPO4 2.86 g/L, KH2PO4 
0.2 g/L, and KCl 0.19 g/mL) was used. All substances 
used as mobile phase, acceptor medium as well as drug 
solution were produced by E Merk and were purchased 
from Asia Lab Yogyakarta.
Methods
Formulation of potassium losartan solution  
In a 5 mL of volumetric flask, potassium losartan weighed 
accurately was filled in to get a concentration as listed in 
Table 1.  About 0.75 mL of propylene glycol was added 
and followed by dissolving the drug using ultrasonicator. 
Citric buffer was added to get 5 mL drug solution. 
Transdermal transport observation
The male Wistar rat skin was excised after being sacrificed 
by introduced in chloroform saturated chamber.  The hair 
was cut off by electric clipper, and the fat was removed. 
This clean skin was set up in the vertical diffusion cell 
(Figure 1) followed by receptor compartment filling in 
with PBS pH 7.4 and immersing magnetic bar prior to set 
up on thermoline (Cimarec).  For formulation I and III the 
transports were started by filling the donor compartment 
with 2 ml formulation.  For formulation II and IV, as 
listed in Table 1, the donor compartment was filled with 
1 mL of oleic acid as a pretreatment.  The magnetic bar 
was stirred and the temperature was maintained at 35OC. 
After pretreatment of formulation II and IV, the oleic acid 
was removed, and the skin was cleaned three times using 
distilled water.  The water trace was absorbed by filter 
paper prior to transport started. The transport was begun 
by filling the donor compartment with 2 ml formulation. 
The aliquot volume of 1.0 mL was withdrawn from 
receptor compartment in scheduled time (0 (blank), 15, 










I 2 Without pretreatment
II 2 1 hour pretreatment
III 10 Without pretreatment
IV 10 1 hour pretreatment
20, 22, 24, 26, 28, and 30 hours), and the fresh receptor 
solution was added to maintain the constant volume of 
receptor compartment.  The concentration of losartan 
(as potassium losartan) was measured using HPLC. 
Chromatograms of Potassium losartan solution in PBS in 
the range of concentration (ng/ml) 20.26, 50.65, 101.13, 
202.26, 506.5, 1013, 2532.5, 5065, 10130, 20260 were 
recorded.  The peak area at the retention time about 9 
minutes has strong correlation against concentration. 
This concentration determination method has been 
validated (Binarjo and Nugroho, 2013).  
Data analysis
Transport profile was analyzed using Lag Time Diffusion 
method. The transport parameters revealed from this 
method are steady state flux (J) and lag time (tlag). 
Permeability (P) was calculated (P=J/Cd) whereas Cd is 
concentration of drug in donor compartment. Diffusion 
coefficient (D) was calculated using the thickness of 
membrane (h) and tlag (D=h
2/6tlag).  The data of P, D, and 
h were used to calculate partition coefficient (K) (K= 
hP/D) (Martin, Bustamante, and Chun, 1993).  Transport 
efficiency (E) was defined as a ratio of drug permeated 
after 30 hours of transport (MT) to available drug in donor 
compartment (MD). Statistical analysis independent 
sample t-test was carried out using software SPSS 11.5, 
(SPSS Inc, 2002).  The difference is said to be significant 
if the critical p-value is less than 0.05.
 
RESULTS AND DISCUSSION
Calibration curve of potassium losartan in PBS pH 
7.4
Calibration curve of potassium losartan in PBS pH 7.4 
is shown in Figure 2.  It is shown that this curve has 
strong linearity and can be used to calculate potassium 
losartan concentration since calculated r is higher than r 
table (0.95) (Muth 1999).
Transdermal transport profile
Figure 3 shows that the steady state condition has been 
reached after 15 hours of transport for all formulation. 
During 30 hours of experiment, there was not any post 
steady state signal detected. Therefore, the transport 
parameters were calculated from 15th to 30th hours of this 
profile and the data is listed in Table 2. 
Based on independent sample t-test (SPSS 11.5 version), 
there was not any difference between steady state 
flux group I and III (p>0.05), it means that losartan 
concentration in donor compartment did not influence 
the flux of transport without oleic acid pretreatment. 
This results was not agree with first Fick’s law (Martin, 
Bustamante, and Chun, 1993).  It is postulated that the 
higher of drug concentration in donor compartment would 
always enhance the rate of transport, but the transport 
efficiency would be decreased (Wester and Maibach, 
1976).  In present research, the rate of transport was not 
increased while the transport efficiency was decreased.
The transport rate which was not increased by the 
enhancement of drug concentration in donor compartment 
can be explained base on the hydrophilicity of permeant 
and the route of transdermal penetration.  Showing the 
pKa value of 3.64 (Meloun, Syrový, and Vrána, 2005), 
based on Handerson-Hasselbach equation the losartan 
solution at pH 5.0 is more than 90% dissociated resulting 
in the low partition coefficient.  As a result, the main 
Table 2.  Losartan transdermal transport parameters in mean + SD (n=3). Flux, lag time, permeability, 
diffusion coefficient, partition coefficient and transport efficiency are symbolized 
by J, Tlag, P, D, K and E respectively





(cm2/hour) K E x10
3
I 679.93+534.49 17.02+0.41 3.3+1.0 3.9+2.6 0.171+0.055 2.7+0.2
II 347.12+147.5 15.04+3.75 1.7+0.8 4.7+1.3 0.069+0.011 2.3+1.7
III 610.34+79.88 14.18+2.44 0.6+0.1 4.8+0.9 0.026+0.007 0.8+0.1
IV 12849.98+4206.0 13.22+3.19 12.8+4.2 5.2+1.2 0.525+0.285 18.7+5.0
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route of transdermal permeation is transappendageal via 
hydrophilic route of sweat pore (Binarjo, 2014).  The 
very small number and very little area of sweat pore 
was likely limited the number of permeant to cross over. 
Therefore, increasing the number of permeant, i.e. donor 
concentration, did not give any significant enhancement 
of absorption rate.  
 
The oleic acid pretreatment increased the transport 
efficiency, resulting in the enhancement of steady state 
flux of group IV in comparison to group III by 21-fold. 
The ability of oleic acid to reduce the decreasing of 
transport efficiency in the higher concentration was also 
shown by the fact that in the low donor concentration, the 
oleic acid pretreatment did not enhance the flux (group I 
vs group II).  Moreover, it was known that this transport 
efficiency enhancement in high drug concentration of 
donor solution was facilitated by the enhancement of 
partition coefficient by 20-fold, resulting in the change 
of main route of permeation from transappendageal to 
intercellular route.
The diffusion coefficient which was not increased 
indicated that the lipid fluidization mechanism (Naik 
et al., 1995) was not appeared.  If the lipid fluidization 
mechanism is occurred, based on Stoke-Einstein 
equation, D=RT/(6лηrN),  the diffusion coefficient will 
be increased (Achuthan et al., 2011).  Lipid fluidization 
mechanism decreases the viscosity (η) of membrane, and 
based on that equation above, the diffusion coefficient 
will increase.  
In vivo prediction
The in vivo prediction of transdermal delivery was 
started by calculating the appropriate area of application 
to reach the desired plasma level in the therapeutics 
Figure 2.  Calibration curve of potasium losartan in PBS pH 7.4.  
The linear equation is y = 0.7013x – 2.4466 with r = 0.999991
Figure 3.  Losartan transdermal transport profile   The transport parameters are shown in 




windows.  Since the rate of drug entering to the body 
(rate in) is equivalent to the rate of elimination (rate 
out), the plasma level in desired level will be constant, 
similar to intra vena infusion administration.  The rate 
in of delivery is the total flux (JT=J*A), while the rate 
out is the zero order rate of elimination (k
0
=Cp*Vd*k). 
The symbol of J, A, Cp, Vd, and k represent steady state 
flux, surface area of application, desired plasma level in 
therapeutics window, distribution volume, and first order 
constant of drug elimination respectively. 
Unfortunately, the effective plasma level of losartan has 
not been defined yet clearly, because its metabolite also 
has an antihypertensive activity (Choi et al., 2009).  Lee 
and coworkers plotted the pharmacokinetics profile of 
losartan. By assuming the activity of losartan appear at 1 
hour after administration, based on the pharmacokinetics 
profile the plasma level of losartan (Cp) was 10 ng/mL. 
This work also suggested that the value of k is 0.21 hr-1 
(Lee et al., 2003).  The Vd of losartan is 32 L (Lacy, 
Armstrong, and Ingrim 1998).  Using these data, the 
application of formulation in group IV (flux=12849.98 
ng cm-2 hr-1) required an area of 5.56 cm2 (a square with 
the side of 2.36 cm) to reach the desired plasma level of 
10 ng/ml.  This area is reasonable in topical application.
The pharmacokinetics profile of transdermal delivery can 
be predicted from in vitro data, which is analyzed using 
lag time diffusion method resulting lag time and flux. 
Cp as a function of application time can be calculated 
based on the equation of intra vena infusion as shown 
in equation 1.
 
The symbol of R represents the rate of delivery of intra 
vena infusion (in ng/hour) which is similar with total 
flux in transdermal delivery. The physical properties of 
the skin require the lag time in transdermal transport 
(delivery).  This condition suggests the derivation of 
equation 1 to equation 2, to be applicable for transdermal 
delivery.  
                            
Pharmacokinetics profile can be predicted using equation 
2.  For the application of formulation in group IV, the 
pharmacokinetics profile prediction is shown in figure 4, 
by using the total flux (Jtotal) and lag time (tlag) are 71445.9 
ng/hr (calculated from 12849.98 ng hr-1cm-2*5.56 cm2) 
and 13.22 hours respectively.
Figure 4 indicates that the drug occurs in the blood after 
10 hours of administration.  The plateau condition which 
Figure 4.  The prediction of losartan pharmacokinetics profile achieved from transdermal 
delivery, with oleic acid pretreatment (__) and without oleic acid pretreatment (---)
Figure 5.  The movement of drug across the skin in in vitro observation (A) and in vivo study (B)
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was started at about 30 hours happened because the 
constant rate in absorption (zero order) was equal to the 
rate constant of elimination.  The first order of elimination 
is prompted to zero order because of the constant of 
plasma level. It is predicted that 2 ml of dosage form 
can be administrated for 48 hours in the constant of rate 
absorption.  Such time is reasonable since for 48 hours of 
application, the drug absorbed was 3.43 mg (calculated 
from 71445.9 ng/h x48 h), while the available drug in 
dosage form was 20 mg (calculated from 10 mg/ml x 
2mL). 
 
Comparing pharmacokinetics profile in figure 4 with 
pharmacokinetics profile of oral delivery in the dosage 
of 50 mg (Lee et al., 2003), it is sound that transdermal 
delivery is better than oral delivery after 10 hours 
of application.  The long duration of lag time in in 
vitro observation is an obstacle, but it is not always 
happened in in vivo condition.  The membrane in in vitro 
observation is thicker since the sampling is withdrawn 
from the receptor compartment.  It is not absolutely 
right that receptor compartment represents the blood 
vessel, as the blood vessel occurs in the dermis, the part 
of the membrane. The schema in Figure 5 shows such 
condition.
Figure 5 proposes that the drug movement is farther in in 
vitro observation.  In in vivo observation the drug reaches 
the capillary vessel in the dermis tissue, or farthest to 
vein blood vessel in sub cutis tissue.  Moreover, the 
fluidity of membrane in viable tissue, as in in vivo 
observation, is higher than that in dead skin.  In the dead 
skin, the membrane is more viscous, and the implication 
is the lower of diffusion coefficient (D).  According to 
the lag time equation, tlag=h
2/6D, the increasing of h (the 
thickness of the membrane) as well as the decreasing of 
D, affect the increase of lag time.
 
CONCLUSION 
Oleic acid pretreatment to the rat skin increased the rate 
of transdermal permeation 21-fold as well as transport 
efficiency of 23-fold for 30 hours of experiment.  It 
is predicted that using such pretreatment, losartan 
transdermal delivery can reach the effective plasma level 
at the ideal surface area of topical application.
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